FDA approves Dificid for oral suspension and for children aged 6 months and over to treat Clostridioides (formerly Clostridium) difficile-associated diarrhea.-Merck Inc.+ Astellas
Related news and insights
Seres Therapeutics announced the presentation of its final 24-week data from the pivotal Phase III ECOSPOR III study evaluating SER 109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI).
Ferring Pharmaceuticals and Rebiotix presented results from the pivotal Phase III PUNCH CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX 2660 in reducing recurrence of Clostridioides difficile infection (CDI) over placebo.
Seres Therapeutics reported positive topline results from the pivotal Phase III ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER 109 for recurrent C. difficile infection (CDI). The study showed that SER 109 administration resulted in a highly statistically significant absolute decrease of 30.2% in the proportion of patients who experienced a recurrence in CDI